For many years, industry commentators have observed that there could be huge untapped therapeutic potential for psychedelics, should the correct development pathways be found.

Investment in this area is now at an all-time high, with waves of neurological research yielding encouraging results, including in depression, where data have shown that people with depressive disorders can react positively to psilocybin-assisted therapy.

In this week's podcast, we speak with Sean McLintock and Clara Burtenshaw, partners at London-based psychedelic healthcare investment fund Neo Kuma Ventures.

With multiple early stage psychedelics firms in its portfolio, Neo Kuma is at the forefront of clinical research into illnesses including depression, PTSD, addiction, inflammation and chronic pain.